{
  "pmid": "41180093",
  "topic": "sepsis_treatment_plan",
  "pdf_path": "Annane_Sepsis_Corpus\\papers\\PMID_41180093\\paper.pdf",
  "sectionizer": "simple_pdfplumber",
  "sections": {
    "Abstract": "Journal of Intensive Medicine 5 (2025) 304â€“312 Contents lists available at ScienceDirect Journal of Intensive Medicine journal homepage: www.elsevier.com/locate/jointm Review Corticosteroids in sepsis Jihene Mahmoud 1, Marie Alice Bovy 1, Nicholas Heming 1 ,2 ,3 , Djillali Annane 1 ,2 ,3 ,âˆ— 1 Department of Intensive Care, Raymond PoincarÃ©Hospital, APHP University Versailles Saint Quentinâ€“University Paris Saclay, Garches, France 2 Institut Hospitalo Universitaire IHU-3 SEPSIS Institute, Garches, France 3 Laboratory of Infection & Inflammationâ€“U1173, School of Medicine, INSERM, University Versailles Saint Quentinâ€“University Paris Saclay, Garches, France a r t i c l e i n f o a b s t r a c t Managing Editor: Jingling Bao/Zhiyu Wang Sepsis is a major health and socioeconomic burden worldwide. Although international guidelines have helped reduce crude mortality rates from sepsis by optimizing infection control and support of vital organ function, Keywords: Molecular biology there are still no specific therapies for sepsis, other than corticosteroids. The aims of this narrative review were Pharmacology to provide readers with the most recent data on corticosteroids, as well as up-to-date evidence regarding their Preclinical models effects in",
    "Method": "patients with sepsis. Corticosteroids regulate the function of most cell types involved in host response Clinical trials to infections, through both genomic and non-genomic effects, reprogramming immune cells (via regulation of Systematic reviews mitochondrial metabolism) toward anti-inflammatory types, restoring endothelial cell function and endothelium Guidelines integrity, facilitating epithelium repair, and restoring vascular smooth muscle function, as well as organ perfusion. In patients with sepsis, these effects are achieved using supraphysiological doses of corticosteroids, equating to approximately 200 mg/day of hydrocortisone equivalent for 5â€“15 days, depending on the clinical context. The molecular and cellular effects of corticosteroids translate into prevention and reversal of the need for vasopressor, respiratory, and renal supportive therapies, as well as acceleration of organ function resolution, shorter intensive care unit (ICU) and hospital stays, and improved short- and mid-term survival. Remaining gaps in knowledge and evidence to inform practice include insufficient data about the effects of corticosteroids in children, a lack of reliable biomarkers to distinguish those patients who can benefit from treatment, and inadequate information about the effects of corticosteroids on the long-term sequelae of sepsis. The Burden of Sepsis ter sepsis develop new health problems, with annual costs of â‚¬6.8 billion.[ 5 ] In 2017, almost half of all sepsis cases globally The social, economic, and health burdens of sepsis, which occurred in children, with approximately 20 million cases and is defined as life-threatening organ dysfunction triggered by 2.9 million deaths in children aged < 5 years. Analysis of the an abnormal host response to invading microorganisms,[ 1 ] are 2016 Kidsâ€™ Inpatient Database (KID) dataset in the US iden- heavy worldwide. Among organisms that cause sepsis, Strepto- tified 12,297 patients of 0â€“21 years old with sepsis admitted coccus pneumoniae, Streptococcus aureus, Escherichia coli, Kleb- to 1253 hospitals, and determined a crude mortality rate of siella pneumoniae , and Pseudomonas aeruginosa account for more 14.6 %.[ 6 ] Risk of death differed according to patient ethnic- than two-thirds of cases, and there is a high prevalence of mul- ity, geographic region, and insurance status.[ 7 ] At 12 months tidrug resistance.[ 2 , 3 ] Although sepsis is a major threat to EU following pediatric intensive care unit (ICU) admission for sep- and US populations, it disproportionally affects the most vul- tic shock, 13 % of patients had died, and 35 % of surviving pa- nerable and low- and middle-income populations, with approx- tients had not regained their previous quality of life.[ 8 ] In the imately 50 (3.4 in EU) million cases and 11 (0.68 in EU) mil- European Union Childhood Life-threatening Infectious Disease lion deaths annually.[ 4 ] Given population growth and aging, Study (EUCLIDS) study of 2844 patients aged 1 month to 18 cases of sepsis are predicted to double by 2050.[ 2 ] Furthermore, years, the main sources of sepsis were pneumonia (18 %), cen- around three-quarters of patients who survive for 3 years af- tral nervous system (17 %), and soft tissue infection (9 %), and âˆ— Corresponding author: Djillali Annane, Sepsis Institute, Department of Intensive Care Medicine, Raymond PoincarÃ©Hospital, APHP University Versailles Saint Quentinâ€“University Paris Saclay; General Intensive Care Unit, Raymond PoincarÃ©Hospital (APHP), UniversitÃ©Paris Saclay-UVSQ, 104, Boulevard Raymond PoincarÃ© 92380, Garches, France E-mail address: djillali.annane@aphp.fr (D. Annane) . https://doi.org/10.1016/j.jointm.2025.08.006 Received 20 June 2025; Received in revised form 20 July 2025; Accepted 12 August 2025 Available online 19 September 2025 Copyright Â©2025 The Author(s). Published by Elsevier B.V. on behalf of Chinese Medical Association. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) J.Mahmoud,M.A.Bovy,N.Hemingetal. JournalofIntensiveMedicine5(2025)304â€“312 causal microorganisms included Neisseria meningitidis (9 %), S. receptor signaling in mast cells, macrophages, basophils, and aureus (8 %), S. pneumoniae (8 %), and group A streptococcus eosinophils; (2) increasing histamine release from mast cells; (6 %).[ 9 ] In 2017, the World Health Organization urged state (3) polarization of macrophages toward type 2, with decreased members to act. Evidence-based guidelines,[ 10 ] including early proinflammatory cytokine production, increased release of anti- source control, antimicrobials, and vital organ function support, inflammatory molecules, and elevated phagocytosis activity; (4) have contributed to a reduction in sepsis mortality.[ 11 ] With the increasing neutrophil production; and (5) increasing apoptosis exception of corticotherapy in patients with septic shock,[ 12 , 13 ] of basophils and eosinophils. Glucocorticoids also increase nat- no specific interventions are available for sepsis.[ 10 , 14 ] Hyper- ural killer cell activation and dendritic cell apoptosis, while in- and hypo-inflammation are concurrent, sustained, and vary ac- hibiting their maturation and capacity to produce proinflamma- cording to pathogen and host characteristics.[ 15 , 16 ] Key chal- tory cytokines and present antigen. lenges include the provision of dynamic characterization (pre- The role of glucocorticoids in immune cell metabolism has re- diction) of individual risks and response to treatments (treatable cently been unraveled.[ 29 , 30 ] Glucocorticoids reprogram inflam- traits).[ 17 , 18 ] matory macrophages into anti-inflammatory cells by modulat- ing mitochondrial function, inhibiting glycolysis and hypoxia- induced factor 1 alpha, and stimulating itaconate, which coun- The Pharmacological Basis of Corticotherapy for Sepsis teracts succinate accumulation resulting from stalling of the tri- carboxylic acid cycle. The effects of glucocorticoids in restoring A recent review has summarized 75 years of discoveries about the molecular mechanisms of action of corticosteroids.[ 19 ] the mitochondrial network are GR-dependent and mainly non- genomic via GR interaction with pyruvate dehydrogenase.[ 31 ] Corticosteroids act via their receptors: glucocorticoid receptor (GR), encoded by the NR3C1 gene, and mineralocorticoid re- ceptor (MR), encoded by NR3C2 . While GR is present in al- Preclinical Evidence for Corticosteroid Use in Sepsis most all cells, MR only binds glucocorticoids in kidney and brain.[ 19 ] Inactive GR resides in the cytoplasm, stabilized by In various animal models (rabbits and dogs), structural chaperone proteins, while the glucocorticoidâ€“GR complex traps smooth muscle alterations that cause decreased vasomotor tone nuclear factor-kappaB (NF- ðœ…B) in the cytoplasm, preventing are fully reversed by dexamethasone, with subsequent restora- its nuclear translocation. The main active GR isoform, GR al- tion of norepinephrine contractility.[ 32 ] These beneficial effects pha, comprises 777 amino acids with the following domains: of dexamethasone vary according to its pharmacological for- an N-terminal transactivation domain, activation domain 1, a mulation, with disodium phosphate ester having substantial ef- DNA-binding domain, and a ligand-binding domain, and acti- fects, while sodium sulfate ester was ineffective.[ 33 ] Methyl- vation domain 2. After translocation to the nucleus, activated prednisolone is also reported to have cardiovascular protective GR proceeds through a stepwise process, starting from binding effects in primates challenged with intravenous endotoxin.[ 34 ] to DNA at GR binding sites, followed by recruitment of coreg- Furthermore, the protective cardiovascular effects of corticos- ulators (including nuclear receptor coactivators 1â€“3 and nu- teroids have been demonstrated at the regional circulation level clear receptor corepressors 1â€“2). Next, GR monomers inhibit the in the liver,[ 35 , 36 ] gut,[ 37 ] brain,[ 38 ] lung,[ 39 ] and kidney.[ 40 ] The proinflammatory transcription factors, NF- ðœ…B and AP1, thereby mechanisms underlying the cardiovascular protection exerted repressing expression of their downstream genes (transrepres- by corticosteroids include: (1) facilitation of neuronal excitabil- sion), while GR dimers binds to glucocorticoid responsive ele- ity, with enhancement of central sympathetic outflow;[ 41 ] (2) ments (GRE) to induce (transactivate) or negative GRE to inhibit decreased in sepsis-induced vascular permeability[ 42 , 43 ] (3) in- gene expression. There are also other GR monomer binding sites, hibition of nitric oxide synthase,[ 44 ] group II secretory phos- and tetrameric GR complexes can also bring two glucocorticoid pholipase A2,[ 45 ] cyclooxygenase metabolites,[ 46 ] endothelin- binding sites together.[ 20 , 21 ] Beyond the transrepression through 1,[ 47 ] ATP-sensitive potassium channels,[ 48 ] and NF- ðœ…B;[ 49 ] and GR monomers and transactivation by GR dimers, activated GR (4) upregulation of adrenomedullin,[ 50 ] the RhoA/ RhoA kinase also upregulates the Dusp1,[ 22 ] Anxa1,[ 23 ] Gilz,[ 24 ] and A20[ 25 ] (ROCK), extracellular signal â€‘regulated kinase (ERK), and p38 anti-inflammatory genes. signaling pathways,[ 51 ] and norepinephrine-induced shrinkage Glucocorticoids also have rapid non-genomic effects, result- and actin cytoskeleton rearrangement.[ 52 ] ing from their interactions with membrane sites, the chaperone Preclinical evidence for attenuation of inflammation in sepsis proteins that are released when glucocorticoids bind to GR, or by corticosteroids is also abundant.[ 53â€“56 ] Methylprednisolone from phosphoinositide 3-kinase competition.[ 26 ] can restore phagocytic and opsonin activities in the reticuloen- The main effects of corticosteroids relevant to their appli- dothelial system.[ 53 ] Furthermore, glucocorticoids preserve neu- cation in patients with sepsis are summarized in Table 1 . The trophil function in dogs with E. coli sepsis,[ 54 ] inhibit the release molecular effects of corticosteroids are cell-type specific.[ 27 ] At and lethality of tumor necrosis factor and IL-1 in mice,[ 55 ] re- the level of adaptive immunity, glucocorticoids inhibit polariza- duce Kupffer cells (a major source of cytokines in sepsis),[ 56 ] tion toward T helper (TH) 1 and TH17 cells and correspond- lower plasma hydrogen sulfide concentration,[ 57 ] prevent and ing proinflammatory cytokines, while increasing polarization reverse NF- ðœ…B expression,[ 58 ] reduce mitochondrial injury, but toward TH2 cells.[ 28 ] Furthermore, they increase apoptosis and preserved cytochrome c oxidase, and suppress proapoptotic decrease signaling by TH cells, cytotoxic T cells, and B cells, proteins,[ 59 ] reverse lipopolysaccharide (LPS)-induced Toll-like while upregulating B cell production of B lymphocyte-induced receptor 4 and myeloid differentiation factor 2 expression,[ 60 ] maturation protein 1 and interleukin (IL)-10. Glucocorticoid and suppress dendritic cell release of IL-12.[ 61 ] Together, the effects on innate immunity include: (1) decreasing Toll-like effects of corticosteroids on the cardiovascular system and in- 305 J.Mahmoud,M.A.Bovy,N.Hemingetal. JournalofIntensiveMedicine5(2025)304â€“312 Table 1 Summary of corticosteroid effects. Systems/functions Molecular/cellular Preclinical Clinical Immunity Adaptive Inhibit polarization toward TH1 and Restore the reticuloendothelial Increase in plasma levels of CXCL9 TH17 system, phagocytic, and opsonin and CXCL10, and of granzymes A and Increase polarization toward TH2 activities B Increase apoptosis and decrease Preserve neutrophil function Modulate release of soluble adhesion signaling of cytotoxic T and B cells Decrease Kupfer cells molecules Upregulate B cell formation Reverse LPS induced TLR4 and MD2 Decrease neutrophil activation Upregulate IL-10 expression levels Decrease plasma levels of IL-6, IL-1, Decrease TLR signaling Prevent and reverse NF- ðœ…B expression and IL-8 Increase histamine release Inhibit TNF and IL-1 Decrease plasma levels of soluble TNF Polarization toward type 2 Suppress dendritic cell release of receptors 1 and 2, and of IL-10 macrophages IL-12 Decrease proinflammatory cytokines Protect the mitochondria by Increase anti-inflammatory cytokines preserving cytochrome c and and phagocytic activities suppressing proapoptotic proteins increase neutrophil production and NK cell activation Increase apoptosis of dendritic cells and decrease their function Metabolism Modulation of mitochondrial function Inhibit glycolysis and hypoxia-induced factor 1 alpha Stimulate itaconate Inhibit succinate accumulation Stalling of the tricarboxylic acid cycle Cardiovascular function Facilitate neuronal excitability Increase vasomotor tone Restore vascular responsiveness to Increase central sympathetic outflow Increase sensitivity to norepinephrine norepinephrine, vasopressin, and Upregulate adrenomedullin, angiotensin 2 RhoA/ROCK, ERK, and p38 signaling, Accelerate weaning from vasopressors norepinephrine shrinkage of nucleus, Prevent the need for vasopressor and rearrangement of the initiation in CAP cytoskeleton Decrease vascular permeability Inhibit inducible NO synthase, cyclooxygenase 2, phospholipase, and ATP-sensitive K+ channels Reverse LPS/sepsis-induced Accelerate weaning from respiratory alterations in kidney, liver, lung, gut, support and brain regional circulation, and Prevent the need for respiratory decrease immune cell infiltration and support in CAP inflammation Reduce the need for renal Reduce mortality replacement therapy Accelerate resolution of organ function, as assessed by SOFA scores Reduce length of hospital stay Reduce mortality CAP: Community-acquired pneumonia; ERK: Extracellular signal â€‘regulated kinase; IL: Interleukin; LPS: Lipopolysaccharide; NK: Natural killer; NO: Nitric oxide; SOFA: Sequential organ failure assessment; TH1: T helper 1; TLR: Toll-like receptor; TNF: Tumor necrosis factor. flammation translate into prevention or restoration of organ inhibition of these mediators by corticosteroids may explain damage and function,[ 59 , 62 , 63 ] as well as survival in various ani- the restoration of norepinephrine responsiveness.[ 73 ] Hydrocor- mal models.[ 35 , 64 , 65 ] In experimental sepsis, the favorable effects tisone can also restore blood pressure response to alpha1 ag- of corticosteroids are modulated by numerous factors, among onists in patients with septic shock,[ 74 , 75 ] and enhances pres- which is macrophage migration inhibitory factor[ 66 ] and trig- sure sensitivity to catecholamines, which translates into accel- gering receptor expressed on myeloid cells-2[ 67 ] have negative erated vasopressor withdrawal in this context.[ 12 , 76â€“79 ] Analysis regulatory effects, while IL-10[ 68 ] and Gilz[ 69 ] exhibit positive of pooled data from 18 trials ( n = 6938 participants) revealed a regulatory activity. Preclinical studies also suggest a critical role risk ratio (RR) for shock reversal at day 7 of 1.22 (95 % confi- for endothelial expression of GR[ 70 ] and MR.[ 71 ] dence interval [CI]: 1.13 to 1.33, P < 0.00001) and of 1.05 (95% CI: 1.03 to 1.07, P < 0.00001) at day 28 in favor of corticos- Clinical Evidence for Corticosteroid Use in Sepsis teroids relative to placebo or usual care.[ 80 ] Furthermore, hydro- cortisone prevented the need for vasopressor therapy in patients Corticosteroids reverse cardiovascular failure with community-acquired pneumonia-related sepsis,[ 81 ] but not in those with unselected sepsis.[ 82 ] In healthy volunteers, endotoxin-induced hyporesponsive- ness to incremental doses of norepinephrine, and this was Corticosteroids attenuate inflammation prevented by intravenous administration of hydrocortisone.[ 72 ] Endotoxin-induced endothelial dysfunction is, at least partly, In healthy volunteers challenged with LPS, prednisolone acts related to the effects of proinflammatory mediators (e.g., tu- in a dose-dependent manner to prevent increases in plasma mor necrosis factor [TNF], IL-1, IL-6, and cyclooxygenase), and concentrations of the chemokines, CXCL9 and CXCL10, and of 306 J.Mahmoud,M.A.Bovy,N.Hemingetal. JournalofIntensiveMedicine5(2025)304â€“312 granzyme A and B levels,[ 83 ] as well as influencing the release mortality relative to administration of hydrocortisone alone,[ 91 ] of soluble endothelial adhesion molecules.[ 84 ] In patients with consistent with the findings of the Corticosteroids and Intensive septic shock, corticosteroids hasten the decrease in circulating Insulin Therapy for Septic Shock (COIITSS) trial.[ 92 ] IL-6,[ 85â€“87 ] IL-1,[ 86 ] and IL-8.[ 87 , 88 ] Furthermore, hydrocortisone reduced endothelial cell (soluble E-selectin) and neutrophil (ex- Corticosteroids have uncertain effects on long-term cognitive pression of CD11b, CD64) activation, and reduced the anti- dysfunction and mental health inflammatory response (i.e., soluble tumor necrosis factor re- ceptors I and II and IL-10).[ 87 ] In peripheral blood monocytes, It has been reported that treatment with high concentrations human leukocyte antigen-DR expression was only slightly de- of glucocorticoids may alter hippocampus and prefrontal cortex pressed in response to hydrocortisone, whereas in vitro phago- function, with subsequent impairment of memory and cognitive cytosis and levels of the monocyte-activating cytokine, IL-12, function.[ 93 ] Nevertheless, glucocorticoids may prevent post- increased.[ 87 ] Furthermore, premature withdrawal of hydrocor- traumatic stress disorders.[ 93 ] Future studies should prospec- tisone resulted in a rebound in inflammation and vasopressor tively assess the long-term effects of hydrocortisone and/or flu- dependency.[ 87 ] drocortisone on cognitive function and mental health. Corticosteroids reverse organ failure Corticosteroid-associated complications in sepsis In patients with septic shock, corticosteroids improve the par- A meta-analysis of 47 trials ( n = 13,893 participants) specif- tial pressure of oxygen /fraction of inspired oxygen (PaO 2 /FiO 2 ) ically addressed the issue of serious short-term complications ratio[ 85 ] and accelerate ventilator weaning.[ 12 , 77â€“79 ] Similarly, of corticotherapy for sepsis, community-acquired pneumonia, corticosteroids prevent ventilator dependency in patients with and acute respiratory distress syndrome (ARDS).[ 94 ] The study community-acquired pneumonia-related sepsis.[ 85 ] In a sec- found, with moderate certainty, that corticosteroids did not in- ondary analysis of the Adjunctive Corticosteroid Treatment in crease the risk of gastroduodenal bleeding (relative risk = 1.08, Critically Ill Patients with Septic Shock (ADRENAL) trial, the 95 % CI: 0.87 to 1.34) or of superinfections (relative risk = 0.97, odds ratio for the need for renal replacement therapy was 0.84 95 % CI: 0.89 to 1.05). Furthermore, the",
    "Conclusion": "results of this meta- (95 % CI: 0.70 to 0.99; P = 0.04), in favor of hydrocortisone ther- analysis indicated that corticosteroids may not increase the risk apy as compared to placebo.[ 89 ] Analysis of pooled data from 17 of muscle weakness (relative risk = 1.22, 95 % CI: 1.03 to 1.45) or trials ( n = 3220 participants) detected aâˆ’1 .27 (95 % CI:âˆ’1 .63 to neuropsychiatric disorders (relative risk = 1.19, 95 % CI: 0.82 to âˆ’ 0.92, P < 0.00001) mean difference in Sequential Organ Fail- 1.74), and there was moderate to high certainty of an increased ure Assessment ( SOFA) score at day 7 in favor of corticosteroids risk of hyperglycemia (relative risk = 1.21, 95 % CI: 1.11 to 1.31) compared to placebo or usual care.[ 80 ] or hypernatremia (relative risk = 1.59, 95 % CI: 1.29 to 1.96). These findings are consistent with more recent data.[ 80 ] Fur- Corticosteroids reduce length of hospital stay and mortality thermore, use of corticosteroids during the recent coronavirus disease (COVID)-19 pandemic appears to have been associated Individual trials have reported variable effects of corticos- with an increased risk of opportunistic infections (e.g., tubercu- teroids on short-term (up to 90 days) mortality in adults with losis, fungi, Pneumocystis jirovecii ).[ 95 ] septic shock.[ 12 , 77 â€“79 ] Two trials of hydrocortisone plus flu- drocortisone reported significant reductions in mortality,[ 12 , 77 ] Use of Corticosteroids for Sepsis in Clinical Practice while another two trials found no evidence that hydrocorti- sone reduced mortality.[ 78 , 79 ] Analysis of the best evidence from The authorsâ€™ preferences regarding corticosteroid use in sep- pooled data from the literature for mortality at 28 days, includ- sis are summarized in Figure 1 . ing 22,915 participants from 72 trials, revealed a RR of 0.89 (95 % CI: 0.84 to 0.95; P = 0.0007, random effects model) in fa- Patient selection vor of corticosteroids vs. placebo or usual care.[ 80 ] Likewise, corticosteroids reduced 90-day mortality (13 trials, n = 8360; The most recent guidelines suggest administering corticos- RR = 0.89, [95 % CI: 0.82 to 0.97]; P = 0.01), ICU mortality (24 teroids to adult patients: (1) with septic shock (conditional trials, n = 8866; RR = 0.90, [95 % CI: 0.83 to 0.98], P = 0.01), recommendation, low certainty of evidence); (2) with ARDS and hospital mortality (40 trials, 17,459 participants; RR = 0.90, (conditional recommendation, moderate certainty of evidence); 95 % CI: 0.84 to 0.97; P = 0.004). The effects of corticosteroids and (3) hospitalized with severe bacterial community-acquired on long-term mortality were less certain (12 trials, 8468 partic- pneumonia.[ 96 ] The findings of the most recent and comprehen- ipants; RR = 0.97, 95% CI: 0.91 to 1.03; P = 0.27). A retrospective sive systematic review and meta-analysis are consistent with analysis of stepwise change in hydrocortisone administration these recommendations.[ 80 ] Indeed, this meta-analysis found and 90-day mortality, using data from the ADRENAL trial,[ 79 ] that, compared to placebo or usual care, corticosteroids likely found an increase in the use of hydrocortisone therapy from reduce 28-day mortality (RR = 0.89, 95 % CI: 0.84 to 0.95; 72 28 % to 43 % ( P < 0.0001) and a decrease in 90-day mortality trials, n = 22,915; moderate-certainty evidence), with no evi- (14 % vs. 24 %, adjusted hazard ratio for hydrocortisone effect dence of differences in response to treatment between: chil- 0.81; 95 % CI: 0.65 to 0.99; P = 0.044).[ 90 ] Another real-life anal- dren and adults (test for subgroup differences: ðœ’2 = 0.34, de- ysis of the use of corticosteroids found that, in norepinephrine- grees of freedom [df] = 1, P = 0.56; I2 = 0 %); patients with or treated septic shock, treatment with hydrocortisone plus fludro- without critical illness associated with corticosteroid insuffi- cortisone resulted in a significant âˆ’ 3 % absolute reduction in ciency (test for subgroup differences: ðœ’2 = 0.20, df = 1, P = 0.66); 307 J.Mahmoud,M.A.Bovy,N.Hemingetal. JournalofIntensiveMedicine5(2025)304â€“312 â€“3 % absolute reduction in hospital mortality with hydrocorti- sone plus fludrocortisone relative to hydrocortisone alone.[ 92 ] In a retrospective study with target trial emulation, using a large healthcare US dataset, the primary composite outcome of death in hospital or discharge to hospice occurred in 1076 (47.2 %) patients treated with hydrocortisone plus fludrocor- tisone and 43,669 (50.8 %) treated with hydrocortisone alone (adjusted absolute risk difference of â€“3.7 %; 95 % CI:4.2 % to â€“ 3.1 %; P < 0.001).[ 91 ] Furthermore, a meta-analysis of individual patient data suggested that hydrocortisone plus fludrocortisone may be superior to hydrocortisone alone in adults with septic shock.[ 98 ] In addition, two trials have found that fludrocortisone given enterally to adults with septic shock is well absorbed and demonstrates reliable pharmacokinetics/pharmacodynamics in these critically ill patients.[ 99 , 100 ] In community-acquired pneumonia-related sepsis, physicians may consider intravenous administration (bolus or continuous infusion) of hydrocortisone at 200 mg daily for 7 days, or for 4â€“8 days according to clinical improvement, and then tapering for 8â€“14 days, or until ICU discharge, depending on which oc- curs first.[ 96 ] Methylprednisolone administration is another po- tential option. The dosing regimen for methylprednisolone may Figure 1. Decision tree for the use of corticosteroids in intensive care unit adults be intravenous 0.5 mg/kg every 12 h for 7 days (within 36 h of with sepsis. hospital admission) or starting at 40 mg continuous intravenous ARDS: Acute respiratory distress syndrome; CAP: Community-acquired pneumo- infusion for 7 days, followed by tapering of the daily dose by nia; i.v.: Intravenous injection. half every week.[ 96 ] Finally, in patients with sepsis and ARDS, physicians may administer intravenous dexamethasone 20 mg or patients with varying disease severity (meta-regression, daily for 5 days, then 10 mg daily for 5 days until extubation, P = 0.5013). Nevertheless, there was evidence for significant or methylprednisolone 1 mg/kg intravenous bolus, followed by differences in treatment response according to patient base- continuous intravenous perfusion of 1 mg/kg for 2 weeks, then line phenotype (test for subgroup differences: ðœ’2 = 16.05, df = 4, taper the daily dose by half every week.[ 96 ] P = 0.003; I2 = 75.1 %). More specifically, in uncomplicated sep- The most recent systematic review and meta-analysis sug- sis, corticosteroids may have no effect on 28-day mortality gested that lower doses of corticosteroids given in the first 24 h, (RR = 1.08, 95 % CI: 0.90 to 1.28; P = 0.41; random â€effects model; lower cumulative dose, and longer treatment duration were as- 14 studies, n = 1825). Conversely, corticosteroids likely reduce sociated with a lower RR for dying at 28 days ( P = 0.03, P = 0.02, 28-day mortality in patients with: septic shock (RR = 0.93, 95 % and P = 0.04, respectively).[ 80 ] In contrast, the study found no CI: 0.86 to 1.00; P = 0.04; random â€effects model; 29 studies, evidence for differences in treatment response between patients n = 8871); sepsis and ARDS (RR = 0.59, 95 % CI: 0.42 to 0.83; in which drug treatment was terminated compared with those in P = 0.002; random â€effects model; five studies, n = 496); sepsis which it was tapered off. One study including a crossover trial and community â€acquired pneumonia (RR = 0.68, 95 % CI: 0.54 highlighted that, in patients with septic shock, premature ter- to 0.86; P = 0.001; random â€effects model; 16 studies, n = 3818); mination (before 72 h) of hydrocortisone was associated with a and COVID â€19 â€related sepsis (RR = 0.88, 95 % CI: 0.81 to 0.95; rebound in excessive inflammation and recurrence of shock.[ 87 ] P = 0.002; random â€effects model; seven studies, n = 7764).[ 80 ] There is insufficient evidence to support the use of corticos- Future Challenges teroids in other viral pneumonia, particularly in the treatment of influenza.[ 97 ] Ongoing studies (NCT04381936, NCT02735707) Information about the benefits and risks of corticosteroids may provide more information about the benefits and harms of in children remains insufficient, while ongoing trials may in- corticosteroids in severe influenza. form future clinical practice ( Table 2 ). The optimal dosing reg- imens for corticosteroids in patients with different clinical phe- Corticosteroid regimens notypes require clarification; in particular, whether fludrocorti- sone provides added value warrants further investigation. The For patients with septic shock, the most recent guide- early identification of patients with a high probability of bene- lines suggest continuous intravenous hydrocortisone infusion at fiting from corticosteroids vs. those more likely to be harmed by 200 mg daily, or q6 for 7 consecutive days or up to ICU dis- these drugs is among the top priorities currently under investi- charge, depending which occurs first.[ 96 ] There is no recommen- gation by several groups ( Table 2 ). Several candidate markers dation about the use of fludrocortisone in addition to hydrocor- for harms or benefits from corticosteroids have been identified tisone. Two trials found that a combination of hydrocortisone in the past two decades, including: endocrine markers based (50 mg intravenous bolus q6 for 7 days) with fludrocortisone on steroid hormone response to adrenocorticotropic hormone (50 Î¼g enterally once a day for 7 days) significantly reduced all- tests,[ 77 , 101 ] serum levels of cytokines/chemokines,[ 102 ] intelli- cause mortality relative to placebo.[ 12 , 77 ] A third trial found a gent algorithms,[ 103 , 104 ] and transcriptome signatures.[ 105 , 106 ] 308 J.Mahmoud,M.A.Bovy,N.Hemingetal. JournalofIntensiveMedicine5(2025)304â€“312 Table 2 Ongoing trials evaluating the use of corticosteroids in sepsis. Registration Population Design Corticosteroid dosing Primary outcome Country Sponsor number/acronym regimen NCT05334316 Adults with pneumonia Phase 2 Open-label Dexamethasone vs. usual Adherence to individual USA Mayo Clinic without shock randomized trial on 2 care treatment rule and n = 24 parallel groups CRP-guided corticosteroid treatment NCT05354778 Adults with healthcare or Placebo-controlled Hydrocortisone (100 mg Composite outcome: Brazil Instituto de Assistencia HYDRO-SHIP ventilator-associated randomized trial on 2 q8 for 5 days) vs. placebo Death OR Respiratory Medica ao Servidor pneumonia without parallel groups worsening OR Publico Estadual shock Cardiovascular n = 180 worsening NCT02735707 Children and adults with Multifactorial Adaptive Shock-dependent 90-day all-cause Multinational UMC Utrecht REMAPCap CAP of sufficient severity Platform Trial, open hydrocortisone (200 mg mortality to require ICU admission label daily) and associated with OR Fixed-duration substantial mortality dexamethasone vs. usual n = 20,000 care NCT03401398 Children (1 month to 17 Phase 3, randomized, Hydrocortisone initial New or progressive Multinational Seattle Childrenâ€™s SHIPSS years and 8 months old) placebo-controlled trial bolus of 2 mg/kg multiple organ Hospital with septic shock on 2 parallel groups intravenous (maximum dysfunction syndrome as n = 500 100 mg), followed by assessed using the 1 mg/kg (maximum Pediatric Logistic Organ 50 mg) q6 for a Dysfunction (PELOD-2) maximum of 7 days or instrument until all vasoactive infusions have been discontinued for > 12 h vs. placebo NCT04280497 Adults with sepsis, septic Phase 3, Bayesian Hydrocortisone as 50 mg 90-day mortality and Multination in Assistance Publique RECORDS shock, CAP or sepsis and adaptive, Basket trial, intravenous bolus q6 for Persistent organ France HÃ´pitaux de Paris ARDS, and having at placebo-controlled trial 7 days plus dysfunction (continued least one measured on multiple parallel arms fludrocortisone 50 Î¼g dependency on biomarker to guide enterally once a day for mechanical ventilation, corticosteroids 7 days renal replacement n = capped at 1800 therapy, or vasopressors) and with SOFA score â‰¤ 6 up to 90 days ARDS: Acute respiratory distress syndrome; CAP: Community-acquired pneumonia; CRP: C-reactive protein; ICU: Intensive care unit; SOFA: Sequential organ failure assessment. In summary, the use of supraphysiologic doses of corticos- funded by ERA PerMed (JTC_2021) to Djillali Annane (ANR- teroids for a week or two in patients with sepsis is supported by 21-PERM-0005). biological and pharmacological rationale, evidence from clinical trials, and high-quality systematic reviews and meta-analyses, as Ethics Statement well as clinical practice guidelines. Not applicable. CRediT Authorship Contribution Statement Conflict of Interest Jihene Mahmoud: Writing â€“ original draft, Conceptualiza- tion.Marie Alice Bovy: Writing â€“original draft, Conceptualiza- The authors declare that they have no known competing fi- tion.Nicholas Heming: Writing â€“review & editing, Conceptual- nancial interests or personal relationships that could have ap- ization.Djillali Annane: Writing â€“review & editing, Validation, peared to influence the work reported in this paper. Supervision, Methodology, Funding acquisition, Conceptualiza- Given his role as Editorial Board Member, Djillali Annane tion. had no involvement in the peer-review of this article and has no access to information regarding its peer-review. Full respon- Acknowledgments sibility for the editorial process for this article was delegated to another journal editor. None. Data Availability Funding Not applicable. This work was funded by the Programme Hospitalier de Recherche Clinique 2007 of the French Ministry of So- References cial Affairs and Health (contract P070128), the Programme dâ€™Investissements dâ€™Avenir (ANR-18-RHUS-0004), France 2030 [1] Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). (IAHU-0004-PROMETHEUS), and the iRECORDS project, JAMA 2016;315(8):801â€“10. doi: 10.1001/jama.2016.0287 . 309 J.Mahmoud,M.A.Bovy,N.Hemingetal. JournalofIntensiveMedicine5(2025)304â€“312 [2] Bertagnolio S, Dobreva Z, Centner CM, Olaru ID, DonÃ D, Burzo S, et al. WHO global [27] Franco LM, Gadkari M, Howe KN, Sun J, Kardava L, Kumar P, et al. Immune reg- research priorities for antimicrobial resistance in human health. Lancet Microbe ulation by glucocorticoids can be linked to cell type-dependent transcriptional re- 2024;5(11):100902. doi: 10.1016/S2666-5247(24)00134-4 . sponses. J Exp Med 2019;216(2):384â€“406. doi: 10.1084/jem.20180595 . [3] GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associ- [28] Hardy RS, Raza K, Cooper MS. Therapeutic glucocorticoids: mechanisms ated with 33 bacterial pathogens in 2019: a systematic analysis for the of actions in rheumatic diseases. Nat Rev Rheumatol 2020;16(3):133â€“44. Global Burden of Disease Study 2019. Lancet 2022;400(10369):2221â€“48. doi: 10.1038/s41584-020-0371-y . doi: 10.1016/S0140-6736(22)02185-7 . [29] Scholtes C, GiguÃ¨re V. Transcriptional control of energy metabolism [4] Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. by nuclear receptors. Nat Rev Mol Cell Biol 2022;23(11):750â€“70. Global, regional, and national sepsis incidence and mortality, 1990â€“2017: anal- doi: 10.1038/s41580-022-00486-7 . ysis for the Global Burden of Disease Study. Lancet 2020;395(10219):200â€“11. [30] Stifel U, Caratti G, Tuckermann J. Novel insights into the regulation of cellu- doi: 10.1016/S0140-6736(19)32989-7 . lar catabolic metabolism in macrophages through nuclear receptors. FEBS Lett [5] Fleischmann-Struzek C, Rose N, Freytag A, Spoden M, Prescott HC, Schettler A, 2022;596:2617â€“29. doi: 10.1002/1873-3468.14474 . et al. Epidemiology and costs of postsepsis morbidity, nursing care dependency, [31] Auger JP, Zimmermann M, Faas M, Stifel U, Chambers D, Krishnacoumar B, et al. and mortality in Germany, 2013â€“2017. JAMA Netw Open 2021;4(11):e2134290. Metabolic rewiring promotes anti-inflammatory effects of glucocorticoids. Nature doi: 10.1001/jamanetworkopen.2021.34290 . 2024;629(8010):184â€“92. doi: 10.1038/s41586-024-07282-7 . [6] Mitchell HK, Reddy A, Montoya-Williams D, Harhay M, Fowler JC, et al. Hospital [32] Ashford T, Palmerio C, Fine J. Structural analogue in vascular muscle to outcomes for children with severe sepsis in the USA by race or ethnicity and insur- the functional disorder in refractory traumatic shock and reversal by cor- ance status: a population-based, retrospective cohort study. Lancet Child Adolesc ticosteroid: electron microscopic evaluation. Ann Surg 1966;164(4):575â€“86. Health 2021;5(2):103â€“12. doi: 10.1016/S2352-4642(20)30341-2 . doi: 10.1097/00000658-196610000-00004 . [7] Moorthy GS, Young RR, Smith MJ, White MJ, Hong H, Kelly MS. Racial in- [33] Imai T, Sakuraya N, Fujita T. Comparative study of anti-endotoxic potency of dex- equities in sepsis mortality among children in the United States. Pediatr Infect Dis amethasone based on its different ester types. Circ Shock 1979;6(4):311â€“21 . J 2023;42(5):361â€“7. doi: 10.1097/INF.0000000000003842 . [34] Balis JU, Rappaport ES, Gerber L, Fareed J, Buddingh F, Messmore HL. A primate [8] Zimmerman JJ, Banks R, Berg RA, Zuppa A, Newth CJ, Wessel D, et al. model for prolonged endotoxin shock. Blood-vascular reactions and effects of glu- Trajectory of mortality and health-related quality of life morbidity following cocorticoid treatment. Lab Invest 1978;38(4):511â€“23 . community-acquired pediatric septic shock. Crit Care Med 2020;48(3):329â€“37. [35] Balis JU, Paterson JF, Shelley SA, Larson CH, Fareed J, Gerber LI. Glucocorticoid doi: 10.1097/CCM.0000000000004123 . and antibiotic effects on hepatic microcirculation and associated host responses in [9] MartinÃ³n-Torres F, Salas A, Rivero-Calle I, Cebey-LÃ³pez M, Pardo-Seco J, Her- lethal gram-negative bacteremia. Lab Invest 1979;40(1):55â€“65 . berg JA, et al. Life-threatening infections in children in Europe (the EUCLIDS [36] Fettman MJ, Hand MS, Chandrasena LG, Cleek JL, Mason RA, Brooks PA, et al. Project): a prospective cohort study. Lancet Child Adolesc Health 2018;2(6):404â€“ Methylprednisolone and gentamicin effects on hepatosplanchnic blood flow and 14. doi: 10.1016/S2352-4642(18)30113-5 . carbohydrate metabolism in endotoxemic Yucatan miniature pigs. Am J Vet Res [10] Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, 1986;47(11):2468â€“76 . et al. Surviving sepsis campaign: international Guidelines for Management [37] Gaffin SL, Gathiram P, Wells MT, JG Brock-Utne. Effect of corticosteroid pro- of Sepsis and Septic Shock 2021. Crit Care Med 2021;49(11):e1063â€“143. phylaxis on lipopolysaccharide levels associated with intestinal ischemia in doi: 10.1097/CCM.0000000000005337 . cats. Crit Care Med 1986;14(10):889â€“91. doi: 10.1097/00003246-198610000- [11] Venkatesh B, Schlapbach L, Mason D, Wilks K, Seaton R, Lister P, et al. Impact 00012 . of 1-h and 3-h sepsis time bundles on patient outcomes and antimicrobial use: [38] Jr Emerson TE, RM Raymond. Methylprednisolone in the prevention of cerebral a before and after cohort study. Lancet Reg Health West Pac 2021;18:100305. hemodynamic and metabolic disorders during endotoxin shock in the dog. Surg doi: 10.1016/j.lanwpc.2021.100305 . Gynecol Obstet 1979;148(3):361â€“6 . [12] Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, et al. [39] Vaage J. Effects of high-dose corticosteroids on the pulmonary circulation. Acta Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med Chir Scand Suppl 1985;526:73â€“82 . 2018;378(9):809â€“18. doi: 10.1056/NEJMoa1705716 . [40] Tsao CM, Ho ST, Chen A, Wang JJ, Li CY, Tsai SK, et al. Low-dose dexametha- [13] RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, sone ameliorates circulatory failure and renal dysfunction in conscious rats with Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. endotoxemia. Shock 2004;21(5):484â€“91. doi: 10.1097/00024382-200405000- N Engl J Med 2021;384(8):693â€“704. doi: 10.1056/NEJMoa2021436 . 00014 . [14] Santacruz CA, Pereira AJ, Celis E, Vincent JL. Which multicenter ran- [41] Koyama S. Effects of methylprednisolone on renal nerve response to stimula- domized controlled trials in critical care medicine have shown reduced tion of medullary pressor area in endotoxin-induced hypotension. Circ Shock mortality? A systematic review. Crit Care Med 2019;47(12):1680â€“91. 1986;20(3):205â€“15 . doi: 10.1097/CCM.0000000000004000 . [42] Al-Kaisi N, Parratt JR, Siddiqui HH, Zeitlin IJ. Feline endotoxin shock: [15] van der Poll T, Shankar-Hari M, Wiersinga WJ. The immunology of sepsis. Immu- effects of methylprednisolone on kininogen-depletion, on the pul- nity 2021;54(11):2450â€“64. doi: 10.1016/j.immuni.2021.10.012 . monary circulation and on survival. Br J Pharmacol 1977;60(3):471â€“6. [16] Cavaillon JM, Annane D. Compartmentalization of the inflammatory doi: 10.1111/j.1476-5381.1977.tb07524.x . response in sepsis and SIRS. J Endotoxin Res 2006;12(3):151â€“70. [43] Tom WW, Dotterrer RM, Villalba M. Steroid effect on capillary permeability in doi: 10.1179/096805106X102246 . gram-negative septic shock. Evaluation by vitreous fluorophotometry. Arch Surg [17] Russell CD, Baillie JK. Treatable traits and therapeutic targets: goals for 1984;119(9):1021â€“4. doi: 10.1001/archsurg.1984.01390210025007 . systems biology in infectious disease. Curr Opin Syst Biol 2017;2:140â€“6. [44] Rees DD, Cellek S, Palmer RM, Moncada S. Dexamethasone prevents the induction doi: 10.1016/j.coisb.2017.04.003 . by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: [18] Maslove DM, Tang B, Shankar-Hari M, Lawler PR, Angus DC, Bail- an insight into endotoxin shock. Biochem Biophys Res Commun 1990;173(2):541â€“ lie JK, et al. Redefining critical illness. Nat Med 2022;28(6):1141â€“8. 7. doi: 10.1016/s0006-291x(05)80068-3 . doi: 10.1038/s41591-022-01843-x . [45] Nakano T, Arita H. Enhanced expression of group II phospholipase A2 gene in the [19] Eiers AK, Vettorazzi S, Tuckermann JP. Journey through discovery of 75 tissues of endotoxin shock rats and its suppression by glucocorticoid. FEBS Lett years glucocorticoids: evolution of our knowledge of glucocorticoid receptor 1990;273(1â€“2):23â€“6. doi: 10.1016/0014-5793(90)81042-m . mechanisms in rheumatic diseases. Ann Rheum Dis 2024;83(12):1603â€“13. [46] SzabÃ³C, Thiemermann C, Vane JR, SzabÃ³C, Thiemermann C, Vane JR. Inhibition doi: 10.1136/ard-2023-225371 . of the production of nitric oxide and vasodilator prostaglandins attenuates the car- [20] Presman DM, Ganguly S, Schiltz RL, Johnson TA, Karpova TS, Hager GL. DNA diovascular response to bacterial endotoxin in adrenalectomized rats. Proc Biol Sci binding triggers tetramerization of the glucocorticoid receptor in live cells. Proc 1993;253(1338):233â€“8. doi: 10.1098/rspb.1993.0108 . Natl Acad Sci USA 2016;113(29):8236â€“41. doi: 10.1073/pnas.1606774113 . [47] HemsÃ©n A, Modin A, Weitzberg E. Increased concentrations of endothelin- [21] Postel S, Wissler L, Johansson CA, Gunnarsson A, Gordon E, Collins B, et al. Quater- 1 messenger RNA in tissues and endothelin-1 peptide in plasma in sep- nary glucocorticoid receptor structure highlights allosteric interdomain communi- tic pigs: modulation by betamethasone. Crit Care Med 1996;24(9):1530â€“6. cation. Nat Struct Mol Biol 2023;30(3):286â€“95. doi: 10.1038/s41594-022-00914-4 . doi: 10.1097/00003246-199609000-00017 . [22] Abraham SM, Lawrence T, Kleiman A, Warden P, Medghalchi M, Tuckermann J, [48] dâ€™Emmanuele di Villa Bianca R, Lippolis L, Autore G, Popolo A, Marzocco S, Sor- et al. Antiinflammatory effects of dexamethasone are partly dependent on in- rentino L, et al. Dexamethasone improves vascular hyporeactivity induced by LPS duction of dual specificity phosphatase 1. J Exp Med 2006;203(8):1883â€“9. in vivo by modulating ATP-sensitive potassium channels activity. Br J Pharmacol doi: 10.1084/jem.20060336 . 2003;140(1):91â€“6. doi: 10.1038/sj.bjp.0705406 . [23] Perretti M, Dâ€™Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolu- [49] Schmidt C, Kurt B, HÃ¶cherl K, Bucher M. Inhibition of NF-kappaB activity prevents tion of inflammation. Nat Rev Immunol 2009;9(1):62â€“70. doi: 10.1038/nri2470 . downregulation of alpha1-adrenergic receptors and circulatory failure during CLP- [24] Ngo D, Beaulieu E, Gu R, Leaney A, Santos L, Fan H, et al. Divergent effects induced sepsis. Shock 2009;32(3):239â€“46. doi: 10.1097/SHK.0b013e3181994752 . of endogenous and exogenous glucocorticoid-induced leucine zipper in animal [50] Hattori Y, Murakami Y, Atsuta H, Minamino N, Kangawa K, Kasai K. Glucocor- models of inflammation and arthritis. Arthritis Rheum 2013;65(5):1203â€“12. ticoid regulation of adrenomedullin in a rat model of endotoxic shock. Life Sci doi: 10.1002/art.37858 . 1998;62(13):PL181â€“9. doi: 10.1016/s0024-3205(98)00049-6 . [25] Oh KS, Patel H, Gottschalk RA, Lee WS, Baek S, Fraser IDC, et al. Anti-inflammatory [51] Zhang T, Shi WL, Tasker JG, Zhou JR, Peng YL, Miao CY, et al. Dexamethasone chromatinscape suggests alternative mechanisms of glucocorticoid receptor action. induces rapid promotion of norepinephrinemediated vascular smooth muscle cell Immunity 2017;47(2):298â€“309. doi: 10.1016/j.immuni.2017.07.012 . contraction. Mol Med Rep 2013;7(2):549â€“54. doi: 10.3892/mmr.2012.1196 . [26] Mohammed SH, Mirdamadi M, Szucs KF, Gaspar R. Non-genomic actions of steroid [52] Shi WL, Zhang T, Zhou JR, Huang YH, Jiang CL. Rapid permissive action of dexam- hormones on the contractility of non-vascular smooth muscles. Biochem Pharmacol ethasone on the regulation of blood pressure in a rat model of septic shock. Biomed 2024;222:116063. doi: 10.1016/j.bcp.2024.116063 . Pharmacother 2016;84:1119â€“25. doi: 10.1016/j.biopha.2016.10.029 . 310 J.Mahmoud,M.A.Bovy,N.Hemingetal. JournalofIntensiveMedicine5(2025)304â€“312 [53] Kaplan JE. Influence of methylprednisolone on reticuloendothelial phagocytic sone on mortality in patients with septic shock. JAMA 2002;288(7):862â€“71. and opsonic function during traumatic and septic shock. Adv Shock Res doi: 10.1001/jama.288.7.862 . 1980;4:11â€“25 . [78] Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, et al. Hydrocor- [54] White GL, White GS. In vitro effects of prednisolone sodium succinate and Es- tisone therapy for patients with septic shock. N Engl J Med 2008;358(2):111â€“24. cherichia coli organisms on neutrophil survival, glucose utilization, and E coli clear- doi: 10.1056/NEJMoa071366 . ance in canine blood. Am J Vet Res 1982;43(6):1103â€“5 . [79] Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R, et al. Ad- [55] Bertini R, Bianchi M, Ghezzi P. Adrenalectomy sensitizes mice to the lethal ef- junctive glucocorticoid therapy in patients with septic shock. N Engl J Med fects of interleukin 1 and tumor necrosis factor. J Exp Med 1988;167(5):1708â€“12. 2018;378(9):797â€“808. doi: 10.1056/NEJMoa1705835 . doi: 10.1084/jem.167.5.1708 . [80] Annane D, Briegel J, Granton D, Bellissant E, Bollaert PE, Keh D, et al. Corti- [56] Chensue SW, Terebuh PD, Remick DG, Scales WE, Kunkel SL. In vivo bi- costeroids for treating sepsis in children and adults. Cochrane Database Syst Rev ologic and immunohistochemical analysis of interleukin-1 alpha, beta and 2025;6(6):CD002243. doi: 10.1002/14651858.CD002243.pub5 . tumor necrosis factor during experimental endotoxemia. Kinetics, Kupffer [81] Dequin PF, Meziani F, Quenot JP, Kamel T, Ricard JD, Badie J, et al. Hydrocortisone cell expression, and glucocorticoid effects. Am J Pathol 1991;138(2):395â€“ in severe community-acquired pneumonia. N Engl J Med 2023;388(21):1931â€“41. 402 . doi: 10.1056/NEJMoa2215145 . [57] Li L, Whiteman M, Moore PK. Dexamethasone inhibits lipopolysaccharide- [82] Keh D, Trips E, Marx G, Wirtz SP, Abduljawwad E, Bercker S, et al. Ef- induced hydrogen sulphide biosynthesis in intact cells and in an ani- fect of hydrocortisone on development of shock among patients with severe mal model of endotoxic shock. J Cell Mol Med 2009;13(8B):2684â€“92. sepsis: the HYPRESS randomized clinical trial. JAMA 2016;316(17):1775â€“85. doi: 10.1111/j.1582-4934.2008.00610.x . doi: 10.1001/jama.2016.14799 . [58] Murphy SH, Suzuki K, Downes M, Welch GL, De Jesus P, Miraglia LJ, et al. [83] de Kruif MD, Lemaire LC, Giebelen IA, Groot AP, Pater JM, van den Pan- Tumor suppressor protein(p)53, is a regulator of NF-kappaB repression by gaart PS, et al. Effects of prednisolone on the systemic release of mediators of the glucocorticoid receptor. Proc Natl Acad Sci USA 2011;108(41):17117â€“22. cell-mediated cytotoxicity during human endotoxemia. Shock 2008;29(4):458â€“61. doi: 10.1073/pnas.1114420108 . doi: 10.1097/shk.0b013e3181598a6a . [59] Choi HM, Jo SK, Kim SH, Lee JW, Cho E, Hyun YY, et al. Glucocorticoids attenuate [84] Lemaire LC, de Kruif MD, Giebelen IA, van Zoelen MA, vanâ€™t Veer C, van der Poll T. septic acute kidney injury. Biochem Biophys Res Commun 2013;435(4):678â€“84. Differential dose-dependent effects of prednisolone on shedding of endothelial ad- doi: 10.1016/j.bbrc.2013.05.042 . hesion molecules during human endotoxemia. Immunol Lett 2008;121(2):93â€“6. [60] Bonin CP, Baccarin RY, Nostell K, Nahum LA, Fossum C, de Camargo MM. doi: 10.1016/j.imlet.2008.09.005 . Lipopolysaccharide-induced inhibition of transcription of tlr4 in vitro is [85] Annane D, SÃ©bille V, Bellissant E. Effect of low doses of corticosteroids in septic reversed by dexamethasone and correlates with presence of conserved shock patients with or without early acute respiratory distress syndrome. Crit Care NF ðœ…B binding sites. Biochem Biophys Res Commun 2013;432(2):256â€“61. Med 2006;34(1):22â€“30. doi: 10.1097/01.ccm.0000194723.78632.62 . doi: 10.1016/j.bbrc.2013.02.002 . [86] Oppert M, Schindler R, Husung C, Offermann K, GrÃ¤f KJ, Boenisch O, et al. [61] Li CC, Munitic I, Mittelstadt PR, Castro E, Ashwell JD. Suppression of dendritic cell- Low-dose hydrocortisone improves shock reversal and reduces cytokine lev- derived IL-12 by endogenous glucocorticoids is protective in LPS-induced sepsis. els in early hyperdynamic septic shock. Crit Care Med 2005;33(11):2457â€“64. PLoS Biol 2015;13(10):e1002269. doi: 10.1371/journal.pbio.1002269 . doi: 10.1097/01.ccm.0000186370.78639.23 . [62] Archer LT, Kosanke SD, Beller BK, Passey RB, Hinshaw LB. Prevention or [87] Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, et al. Immuno- amelioration of morphologic lesions in LD100 E coli-shocked baboons with logic and hemodynamic effects of \"low-dose\" hydrocortisone in septic shock: a steroid/antibiotic therapy. Adv Shock Res 1983;10:195â€“215 . double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit [63] Johannes T, Mik EG, Klingel K, Dieterich HJ, Unertl KE, Ince C. Low-dose Care Med 2003;167(4):512â€“20. doi: 10.1164/rccm.200205-446OC . dexamethasone-supplemented fluid resuscitation reverses endotoxin-induced acute [88] Mussack T, Briegel J, Schelling G, Biberthaler P, Jochum M. Effect of stress renal failure and prevents cortical microvascular hypoxia. Shock 2009;31(5):521â€“ doses of hydrocortisone on S-100B vs. interleukin-8 and polymorphonuclear elas- 8. doi: 10.1097/SHK.0b013e318188d198 . tase levels in human septic shock. Clin Chem Lab Med 2005;43(3):259â€“68. [64] Prager R, Kirsh MM, Dunn E, Nishiyama R, Straker J, Lee R, et al. The bene- doi: 10.1515/CCLM.2005.044 . fits of corticosteroids in endotoxic shock. Ann Thorac Surg 1975;19(2):142â€“52. [89] Donaldson LH, Devaux A, White KC, Rajbhandari D, Cohen J, Bellomo R, et al. doi: 10.1016/s0003-4975(10)63996-3 . Hydrocortisone and risk factors for kidney replacement therapy in septic shock. [65] Hinshaw LB, Archer LT, Beller-Todd BK, Benjamin B, Flournoy DJ, Passey R. Sur- JAMA Netw Open 2025;8(5):e2512279. doi: 10.1001/jamanetworkopen.2025. vival of primates in lethal septic shock following delayed treatment with steroid. 12279 . Circ Shock 1981;8(3):291â€“300 . [90] White KC, Chaba A, Meyer J, Ramanan M, Tabah A, Attokaran AG, et al. Rapid [66] Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, et al. uptake of adjunctive corticosteroids for critically ill adults with septic shock fol- MIF as a glucocorticoid-induced modulator of cytokine production. Nature lowing publication of ADRENAL trial. A multicenter, retrospective analysis of pre- 1995;377(6544):68â€“71. doi: 10.1038/377068a0 . scribing practices in Queensland Intensive Care Units. Anaesth Crit Care Pain Med [67] Ye H, Zhai Q, Fang P, Yang S, Sun Y, Wu S, et al. Triggering receptor expressed 2024;43(6):101435. doi: 10.1016/j.accpm.2024.101435 . on myeloid cells-2 (TREM2) inhibits steroidogenesis in adrenocortical cell by [91] Bosch NA, Teja B, Law AC, Pang B, Jafarzadeh SR, Walkey AJ. Comparative ef- macrophage-derived exosomes in lipopolysaccharide-induced septic shock. Mol fectiveness of fludrocortisone and hydrocortisone vs hydrocortisone alone among Cell Endocrinol 2021;525:111178. doi: 10.1016/j.mce.2021.111178 . patients with septic shock. JAMA Intern Med 2023;183(5):451â€“9. doi: 10.1001/ja- [68] MO CÃ³rdoba-Moreno, Todero MF, Fontanals A, Pineda G, Daniela M, Yoko- mainternmed.2023.0258 . bori N, et al. Consequences of the lack of IL-10 in different endotoxin ef- [92] Annane D, Cariou A, Maxime V, Azoulay E, Dâ€™honneur G, et al., COIITSS Study fects and its relationship with glucocorticoids. Shock 2019;52(2):264â€“73. Investigators Corticosteroid treatment and intensive insulin therapy for sep- doi: 10.1097/SHK.0000000000001233 . tic shock in adults: a randomized controlled trial. JAMA 2010;303(4):341â€“8. [69] Ellouze M, Vigouroux L, Tcherakian C, Woerther PL, Guguin A, Robert O, et al. doi: 10.1001/jama.2010.2 . Overexpression of GILZ in macrophages limits systemic inflammation while in- [93] Hill AR, Spencer-Segal JL. Glucocorticoids and the brain after critical illness. En- creasing bacterial clearance in sepsis in mice. Eur J Immunol 2020;50(4):589â€“602. docrinology 2021;162(3):bqaa242. doi: 10.1210/endocr/bqaa242 . doi: 10.1002/eji.201948278 . [94] Chaudhuri D, Israelian L, Putowski Z, Prakash J, Pitre T, Nei AM, et al. Adverse [70] Goodwin JE, Feng Y, Velazquez H, Sessa WC. Endothelial glucocorticoid receptor effects related to corticosteroid use in sepsis, acute respiratory distress syndrome, is required for protection against sepsis. Proc Natl Acad Sci USA 2013;110(1):306â€“ and community-acquired pneumonia: a systematic review and meta-analysis. Crit 11. doi: 10.1073/pnas.1210200110 . Care Explor 2024;6(4):e1071. doi: 10.1097/CCE.0000000000001071 . [71] Fadel F, AndrÃ©-GrÃ©goire G, Gravez B, Bauvois B, Bouchet S, Sierra-Ramos C, [95] Praphakornmano T, Torvorapanit P, Siranart N, Ohata PJ, Suwanpimolkul G. et al. Aldosterone and vascular mineralocorticoid receptors in murine en- The effect of corticosteroids in developing active pulmonary tuberculosis among dotoxic and human septic shock. Crit Care Med 2017;45(9):e954â€“62. patients with COVID-19. PLoS One 2024;19(10):e0309392. doi: 10.1371/jour- doi: 10.1097/CCM.0000000000002462 . nal.pone.0309392 . [72] Bhagat K, Collier J, Vallance P. Local venous responses to endotoxin in humans. [96] Chaudhuri D, Nei AM, Rochwerg B, Balk RA, Asehnoune K, Cadena R, et al. Circulation 1996;94(3):490â€“7. doi: 10.1161/01.cir.94.3.490 . 2024 focused update: guidelines on use of corticosteroids in sepsis, acute res- [73] Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent piratory distress syndrome, and community-acquired pneumonia. Crit Care Med dilatation in human veins in vivo. Circulation 1997;96(9):3042â€“7. 2024;52(5):e219â€“33. doi: 10.1097/CCM.0000000000006172 . doi: 10.1161/01.cir.96.9.3042 . [97] Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticos- [74] Bellissant E, Annane D. Effect of hydrocortisone on phenylephrineâ€“mean arte- teroids as adjunctive therapy in the treatment of influenza. Cochrane Database rial pressure dose-response relationship in septic shock. Clin Pharmacol Ther Syst Rev 2019;2(2):CD010406. doi: 10.1002/14651858.CD010406. pub3 . 2000;68(3):293â€“303. doi: 10.1067/mcp.2000.109354 . [98] Pirracchio R, Annane D, Waschka AK, Lamontagne F, Arabi YM, Bollaert PE, et al. [75] Annane D, Bellissant E, Sebille V, Lesieur O, Mathieu B, Raphael JC, et al. Im- Patient-level meta-analysis of low-dose hydrocortisone in adults with septic shock. paired pressor sensitivity to noradrenaline in septic shock patients with and with- NEJM Evid 2023;2(6):EVIDoa2300034. doi: 10.1056/EVIDoa2300034 . out impaired adrenal function reserve. Br J Clin Pharmacol 1998;46(6):589â€“97. [99] Polito A, Hamitouche N, Ribot M, Polito A, Laviolle B, Bellissant E, et al. doi: 10.1046/j.1365-2125.1998.00833.x . Pharmacokinetics of oral fludrocortisone in septic shock. Br J Clin Pharmacol [76] Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal 2016;82(6):1509â€“16. doi: 10.1111/bcp.13065 . of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med [100] Walsham J, Hammond N, Blumenthal A, Cohen J, Myburgh J, Finfer S, et al. 1998;26(4):645â€“50. doi: 10.1097/00003246-199804000-00010 . Fludrocortisone dose-response relationship in septic shock: a randomised phase [77] Annane D, SÃ©bille V, Charpentier C, Bollaert PE, FranÃ§ois B, Korach JM, II trial. Intensive Care Med 2024;50(12):2050â€“60. doi: 10.1007/s00134-024- et al. Effect of treatment with low doses of hydrocortisone and fludrocorti- 07616-z . 311 J.Mahmoud,M.A.Bovy,N.Hemingetal. JournalofIntensiveMedicine5(2025)304â€“312 [101] Briegel J, MÃ¶hnle P, Keh D, Lindner JM, Vetter AC, Bogatsch H, et al. [104] Hellali R, Chelly Dagdia Z, Ktaish A, Zeitouni K, Annane D. Corticosteroid sen- Corticotropin-stimulated steroid profiles to predict shock development and sitivity detection in sepsis patients using a personalized data mining approach: mortality in sepsis: from the HYPRESS study. Crit Care 2022;26(1):343. a clinical investigation. Comput Methods Programs Biomed 2024;245:108017. doi: 10.1186/s13054-022-04224-5 . doi: 10.1016/j.cmpb.2024.108017 . [102] KÃ¶nig R, Kolte A, Ahlers O, Oswald M, Krauss V, Roell D, et al. Use of IFN ð›¾/IL10 [105] Wong HR, Atkinson SJ, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, et al. Com- ratio for stratification of hydrocortisone therapy in patients with septic shock. Front bining prognostic and predictive enrichment strategies to identify children with Immunol 2021;12:607217. doi: 10.3389/fimmu.2021.607217 . septic shock responsive to corticosteroids. Crit Care Med 2016;44(10):e1000â€“3. [103] Pirracchio R, Hubbard A, Sprung CL, Chevret S, Annane D. Rapid Recognition of doi: 10.1097/CCM.0000000000001833 . Corticosteroid Resistant or Sensitive Sepsis (RECORDS) Collaborators. Assessment [106] Antcliffe DB, Burnham KL, Al-Beidh F, Santhakumaran S, Brett SJ, Hinds CJ, et al. of machine learning to estimate the individual treatment effect of corticosteroids Transcriptomic signatures in sepsis and a differential response to steroids. From in septic shock. JAMA Netw Open 2020;3(12):e2029050. doi: 10.1001/jamanet- the VANISH randomized trial. Am J Respir Crit Care Med 2019;199(8):980â€“6. workopen.2020.29050 . doi: 10.1164/rccm.201807-1419OC . 312"
  },
  "meta": {
    "findit_url": "http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC12572860&blobtype=pdf"
  }
}